16394-71-1Relevant articles and documents
TRANSFORMED STEROIDS 108. CORRELATION OF OPENING REACTIONS OF 16,17α-CYCLOPROPANO-20-KETOSTEROIDS WITH THE CONFORMATIONS
Kamernitskii, A. V.,Turuta, A. M.,An, Ngo Thi Mai
, p. 669 - 673 (1980)
-
Crystal structure of 3β-acetoxy-17α-hydroxy-16α- methylallopregnan-20-one hemihydrate
Bandhoria, Pankaj,Gupta, Vivek K.,Gupta,Varghese
, p. 427 - 433 (2006)
3β-Acetoxy-17α-hydroxy-16α-methylallopregnan-20-one, C24H38O4?0.5H2O, is an intermediate towards the synthesis of dexamethasone, an important corticosteroid. The compound crystallizes in the monoclinic space group C2 with unit cell parameters: a = 10.665(2) A, b = 7.497(1) A, c = 28.200(4) A, β = 92.74(2)°, Z = 4. The crystal structure has been solved by direct methods and refined to R = 0.0419 for 1579 observed reflections. All rings of the steroid skeleton are trans connected. Rings A, B, and C are all in the chair conformation. Ring D is in envelop conformation. The acetoxy and acetyl substituents are twisted with respect to the average molecular plane of the steroid. The twist along the length of the steroid molecule is negligible [C19-C10???C13-C18 = 2.3°]. In the crystal structure, the water molecule lies on a twofold axis which links the molecules into infinite supramolecular chains through OW-H???O and O- H???OW hydrogen bonds.
Dehydroepiandrosterone (DHEA) congeners for prevention and/or treatment of ulcers
-
, (2008/06/13)
The present invention is related to acute therapeutic uses of dehydroepiandrosterone (DHEA) congeners. These uses include methods for treating or preventing ulcers which comprise administering to a subject either at risk or in need thereof having an ulcer a therapeutic amount of DHEA congener.
Method for enhancing or accelerating re-epithelialization or re-endothelialization of a tissue
-
, (2008/06/13)
The present invention is related to a method for enhancing or accelerating re-epithelialization or re-endothelialization of a tissue. Examples of re-epithelialization in which the invention is particularly suited include, but are not limited to, re-epithelialization of (a) skin following surgical wounds, (b) skin abrasions caused by mechanical trauma, caustic agents or burns, (c) cornea following cataract surgery or corneal transplants, (d) mucosal epithelium (respiratory, gastrointestinal, genitourinary, mammary, oral cavity, ocular tissue, liver and kidney) following infection, nonpathological etiologies or drug therapy, (e) skin following grafting and (f) renal tubule following acute tubular necrosis. Examples of re-endothelialization in which the invention is particularly suited include, but are not limited to, re-endothelialization (or regrowth of endothelium) in blood vessels following angioplasty, and the lysis of fibrin clots or lysis or mechanical disruption of thrombi in coronary arteries. In accordance with the present invention, the time to complete re-epithelialization or re-endothelialization is enhanced or accelerated by administering a dehydroepiandrosterone (DHEA) derivative.